Heidelberg Pharma AG (LON:0QW5)

Market Cap	123.48M +29.3%
Revenue (ttm)	2.63M -64.1%
Net Income	-22.67M
EPS	-0.48
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11
Average Volume	335
Open	3.040
Previous Close	2.810
Day's Range	3.040 - 3.100
52-Week Range	2.320 - 5.420
Beta	0.83
RSI	55.04
Earnings Date	Mar 24, 2026

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic cas...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 114
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QW5

Financial Performance

In fiscal year 2024, Heidelberg Pharma AG's revenue was 6.85 million, a decrease of -30.53% compared to the previous year's 9.86 million. Losses were -19.38 million, -4.74% less than in 2023.

Financial numbers in EUR